Curocell (XKRX:372320) Other Income (Expense) : ₩ Mil (TTM As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Curocell Other Income (Expense)?

Curocell's other income expense for the Curocell's pretax income for the six months ended in Jun. 2023 was ₩1,818.53 Mil.

Curocell Other Income (Expense) Historical Data

The historical data trend for Curocell's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curocell Other Income (Expense) Chart

Curocell Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Other Income (Expense)

-10,764.02

-812.68

-38,410.50

-18,195.37

3,279.28

Curocell Semi-Annual Data
	Jun22	Dec22	Jun23	Dec23
Other Income (Expense)	-15,976.85	-2,218.53	1,818.53	1,460.75

Curocell Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Curocell (XKRX:372320) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Curocell (XKRX:372320) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

11, Gukjegwahak 16-ro, Yuseong-gu, Daejeon, KOR, 34002

Website

https://www.curocellbtx.com

Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.

Curocell (XKRX:372320) Headlines

No Headlines